Replies to post #256770 on Innovation Pharmaceuticals Inc (IPIX)

[JTORENCE]

Desire add the K trial with only 2 patients. No BP is gonna offer big upfront money with trials like that..

[frrol]

There's actually two "why" questions there. First: you can tell most IPIX-aware investors (the "market") don't have much faith in B because they are not assigning much value to it. (That's the low share price. It's clear as day.) It says a deal is not likely.

Second (and this is the "why" you were really asking about): likely, because B-OM was not granted BTD for OM, which was troubling since OM is in such desperate need of therapies and BTD was granted very recently to another Phase 2 drug (Galera's GC4419). Our OM trial results had some hair on it (that's not unusual). With our IBD trial: mucosa inflammation in IBD can be episodic, so even placebo-controlled trials can be hit/miss.

B very likely has real anti-inflammatory properties, and its potential is really enticing, but you can see why BPs are not pulling triggers immediately. They're taking their time, getting comfortable with the data and results, one has apparently gotten cold feet. A deal is not a given. Management insists we've got interest, and I do not doubt that.

[Lemoncat]

It looks like frrol answered them all except for the ABSSSI part. It was our largest, most advanced, and decisively successful trial. B-ABSSSI has an extremely high chance of success in phase 3 and for NDA. I haven't heard anyone argue against that.

The question remains...why haven't we partnered it?

1. The trial costs were too high for us to take it on solo.

2. The value may be lower than what the company thought. Some speculated that it might be held in reserve behind cheaper generic antibiotics for much of the patent life.

3. We used to think that doing a deal on ABSSSI would complicate deal making or give away too much value before the larger anti-inflammatory conditions were explored. I'm not sure this still holds as we appear to be doing a deal on just anti-inflammatory at this time. Could we not do an ABSSSI deal now?

We don't have a good answer. It irks me because ABSSSI is what brought me here. It looked like a shoe-in for success. If it doesn't get started in the next year or two what will it be worth with little time left on the patent?